Mycobacterium tuberculosis complex (MTBC) Lineage 3 (L3) strains are abundant in world regions with the highest tuberculosis burden. To investigate the population structure and the global diversity of this major lineage, we analyzed a dataset comprising 2682 L3 strains from 38 countries over 5 continents, by employing 24-loci mycobacterial interspersed repetitive unit-variable number of tandem repeats genotyping (MIRU-VNTR) and drug susceptibility testing. We further combined whole-genome sequencing (WGS) and phylogeographic analysis for 373 strains representing the global L3 genetic diversity. Ancestral state reconstruction confirmed that the origin of L3 strains is located in Southern Asia and further revealed multiple independent introduction events into North-East and East Africa. This study provides a systematic understanding of the global diversity of L3 strains and reports phylogenetic variations that could inform clinical trials which evaluate the effectivity of new drugs/regimens or vaccine candidates.
16 July 2021 in Antimicrobial Agents and Chemotherapy
Pyrazinamide (PZA) is one of the first-line agents used for the treatment of tuberculosis. However, current phenotypic PZA susceptibility testing in the BACTEC MGIT 960 system is unreliable and false resistance is well documented. Rapid identification of resistance-associated mutations can confirm the phenotypic result. This study aimed to investigate the use of genotypic methods in combination with phenotypic susceptibility testing for confirmation of PZA resistant M. tuberculosis isolates. Sanger sequencing and/or whole genome sequencing were performed to detect mutations in pncA, rpsA, panD and clpC1. Isolates were screened for heteroresistance, and PZA susceptibility testing was performed in the BACTEC MGIT 960 system using a reduced inoculum to investigate false resistance. Overall, 40 phenotypically PZA resistant isolates were identified. Of these, PZA resistance was confirmed in 22/40 (55%) isolates by detecting mutations in pncA, rpsA and panD genes. 16/40 (40%) isolates were found to be susceptible using the reduced inoculum method (i.e. false resistance). No mutations were detected in two PZA resistant isolates. False resistance was observed in isolates with MICs close to the critical concentration. In particular, EAI strains (lineage 1) appeared to have an elevated MIC that is close to the critical concentration. While this study illustrates the complexity and challenges associated with PZA susceptibility testing of M. tuberculosis, we conclude that a combination of genotypic and phenotypic drug susceptibility testing methods is required for accurate detection of PZA resistance.
Mycobacterium abscessus complex (MABC) are multidrug resistant nontuberculous mycobacteria and cause opportunistic pulmonary infections in individuals with cystic fibrosis (CF). In this study, genomic analysis of MABC was performed to gain greater insights into the epidemiology of circulating strains in Ireland. Whole genome sequencing (WGS) was performed on 70 MABC isolates that had been referred to the Irish Mycobacteria Reference Laboratory between 2006 and 2017 across nine Irish healthcare centres. MABC comprised of 52 isolates from 27 CF patients and 18 isolates from 10 non-CF patients. WGS identified 57 (81.4%) as M. abscessus subsp. abscessus (MAB), 10 (14.3%) as M. abscessus subsp. massiliense (MMAS) and 3 (4.3%) as M. abscessus subsp. bolletii (MBOL). Forty-nine isolates (94%) from 25 CF patients were identified as MAB whereas 3 (6%) isolates from 2 CF patients were identified as MMAS. Among non-CF patients, 44% (8/18) were identified as MAB, 39% (7/18) as MMAS and 17% (3/18) as MBOL. WGS detected two clusters of closely related MAB that included isolates from different CF centres. There was greater genomic diversity of MABC among non-CF compared to CF patients. Although WGS failed to show direct evidence of patient to patient transmission among CF patients, there was a predominance of two different strains of MAB. Furthermore, some MABC were closely related to global strains suggesting their international spread. Future prospective real-time epidemiological and clinical data along with contemporary MABC sequence analysis may elucidate sources and routes of transmission among patients infected with MABC.
The study demonstrates the improved sensitivity of the Ultra compared with the Xpert, particularly in smear negative TB disease, for both pulmonary and extrapulmonary samples in a low TB incidence setting. Cycle threshold (Ct) value for both assays was found to positively correlate with time to TB culture positivity, suggesting that Ct and semiquantitative results could be used as indicators of sample MTBC bacillary burden, and thus, perhaps, of transmission potential.
Collaborative genomic and epidemiological investigations identified a tuberculosis outbreak in Vienna as part of a multi-country cluster comprising 57 foreign-born cases of Mycobacterium tuberculosis ST215/Beijing 2.2.1 notified 2021–2025. While 14 of 16 cases in Vienna were considered autochthonous, the diverse geographic origin of clustered cases across nine European countries suggests a common transmission source, possibly linked to migratory routes. Cross-border data exchange and integrated genomic analysis are essential for identifying transmission dynamics in tuberculosis clusters affecting mobile populations.